---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-073144"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2023-12-27T23:59:59+00:00"
generated_at: "2026-06-07T06:45:00.489335+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics announces positive Phase 3 SEQUOIA-HCM results for aficamten in obstructive HCM

## Summary
- Aficamten improved exercise capacity (pVO2) vs placebo: LS mean diff 1.74 mL/kg/min (p=0.000002).
- All 10 prespecified secondary endpoints met with statistical significance (p<0.0001), including KCCQ-CSS and NYHA class.
- Safety profile comparable to placebo; SAEs 5.6% aficamten vs 9.3% placebo; LVEF <50% in 3.5% vs 0.7%.
- No worsening heart failure or treatment interruptions due to low LVEF; full results at upcoming medical conference.

## SEC filing metadata
- accession: 0000950170-23-073144
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2023-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017023073144/0000950170-23-073144-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017023073144/cytk-20231227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-073144
- JSON: https://secwatch.observer/filing/0000950170-23-073144.json
- Plain text: https://secwatch.observer/filing/0000950170-23-073144.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.